Henan Provincial Key Laboratory of Children's Genetics and Metabolic Diseases, Children's Hospital Affiliated to Zhengzhou University, Zhengzhou University, Zhengzhou 450018, China; School of Pharmaceutical Sciences, and Institute of Drug Discovery & Development, Zhengzhou University, 100 Kexue Avenue, Zhengzhou, Henan 450001, China.
Henan Provincial Key Laboratory of Children's Genetics and Metabolic Diseases, Children's Hospital Affiliated to Zhengzhou University, Zhengzhou University, Zhengzhou 450018, China.
Drug Discov Today. 2022 Aug;27(8):2342-2352. doi: 10.1016/j.drudis.2022.05.004. Epub 2022 May 11.
Retinopathy of prematurity is a noticeable retinal abnormality causing common blindness in children. An uncontrolled retinal vasculature in retinopathy of prematurity inflicts vision loss in numerous children despite the accessibility to a wide range of clinical treatments prescribed for retinopathy of prematurity. Apelin/APJ [class A (rhodopsin-like) G-protein-coupled receptor] signaling regulates retinopathy of prematurity augmented with uncontrolled angiogenesis. Antagonists targeting pathological apelin/APJ-signaling-induced angiogenesis could be effective in attenuating retinopathy of prematurity. The therapeutic proficiency of antagonists in diverse modalities: peptides, bioactive molecules and antibodies, targeting apelin peptides or the APJ receptor is discussed in this review. We hypothesize the antagonists could effectively attenuate the retinal vasculature triggered by apelin/APJ signaling activation governing vision impairment in young children.
早产儿视网膜病变是一种明显的视网膜异常，可导致儿童常见失明。早产儿视网膜病变中的未受控制的视网膜血管会导致许多儿童视力丧失，尽管有广泛的临床治疗方法可用于早产儿视网膜病变。Apelin/APJ [A 类（视紫红质样）G 蛋白偶联受体]信号转导调节未受控制的血管生成的早产儿视网膜病变。针对病理性 Apelin/APJ 信号诱导的血管生成的拮抗剂可能在减轻早产儿视网膜病变方面有效。本文综述了针对 Apelin 肽或 APJ 受体的肽、生物活性分子和抗体等不同模式的拮抗剂的治疗功效。我们假设拮抗剂可以有效减轻 Apelin/APJ 信号激活引发的视网膜血管，从而改善幼儿的视力损伤。
